Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "biotech"

833 News Found

Merck appoints David Weinreich as new Global Head of R&D and CMO for Healthcare Business
People | September 03, 2025

Merck appoints David Weinreich as new Global Head of R&D and CMO for Healthcare Business

He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career


Thermo Fisher opens pipette manufacturing site in North Carolina
News | August 28, 2025

Thermo Fisher opens pipette manufacturing site in North Carolina

New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week


FDA approves Coya Therapeutics’ trial of COYA 302 for ALS
News | August 28, 2025

FDA approves Coya Therapeutics’ trial of COYA 302 for ALS

As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya


Enanta files patent infringement suit against Pfizer
News | August 25, 2025

Enanta files patent infringement suit against Pfizer

The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists


Corbion and Kuehnle join forces to develop natural Astaxanthin from algae fermentation
Biotech | August 23, 2025

Corbion and Kuehnle join forces to develop natural Astaxanthin from algae fermentation

Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms


Vivo Bio Tech secures pre-clinical testing contract valued at Rs.10.75 Cr
News | August 22, 2025

Vivo Bio Tech secures pre-clinical testing contract valued at Rs.10.75 Cr

Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies


FDA lifts hold on Rocket Pharma's gene therapy trial
News | August 22, 2025

FDA lifts hold on Rocket Pharma's gene therapy trial

Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort